Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1

Interventions

Specimen Handling 15Biopsy 14fludarabine 12Cytarabine 11Cyclophosphamide 11fludarabine phosphate 10X-Rays 9Whole-Body Irradiation 9venetoclax 8Magnetic Resonance Spectroscopy 8Injections 8asciminib 7Azacitidine 7Nuclear Medicine Department, Hospital 6Mycophenolic Acid 6Busulfan 6decitabine and cedazuridine drug combination 5Tacrolimus 5Phantoms, Imaging 5Melphalan 5Granulocyte Colony-Stimulating Factor 5Filgrastim 5Cyclosporine 5CPX-351 5ruxolitinib 4ivosidenib 4Stem Cell Transplantation 4Peripheral Blood Stem Cell Transplantation 4Idarubicin 4Decitabine 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphatic Irradiation × Myeloid × 30 days × Clear all
NCT06287944 2026-05-18

225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome

City of Hope Medical Center

Phase 1 Recruiting
15 enrolled
LymphoidMyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡